THE INTELLIGENT KNIFE LUCY LOHRMANN CEO, WATERS CORP. ARISTIDIS SIRINAKIS CFO, WATERS CORP. LUCY SHEPHARD CMO, WATERS CORP. JACOB VITKAUSKAS HEAD SURGEON, KINGS COLLEGE, LONDON JESSICA DAWSON HEAD SCIENTIST, IMPERIAL COLLEGE LONDON WHO WE ARE RISK DEVELOPING CANCER DURING THEIR LIFETIME 1 OUT OF 2 MEN 1 OUT OF 3 WOMEN THE PROBLEM 1/8 WOMEN DEVELOP BREAST CANCER 22.9 % OR 46,000 BREAST CANCER PATIENTS HAVE 1< OPERATION BREAST CANCER RECURRENCE THE TWO TECHNOLOGIES ELECTROSURGERYMASS SPECTROMETRY CLINICAL TRIALS IKNIFECT SCANNER CANCER RADIATION ACCELERATOR USD $380,000USD $2,500,000USD $4,000,000 COMPARITIVE COSTS SPENT ON CANCER TREATMENT BY US GOVERNMENT in BILLION USD MARKET SHARE SAVED PER TUMOR REMOVAL SURGERY WITH IKNIFE X INPATIENT SURGERIES BY MEMORIAL SLOAN KETTERING CANCER CENTER IN 2013 = MEDIAN POTENTIAL SAVINGS 11,370 4,000 USD 45.5 MILLION USD POTENTIAL SAVINGS FEWER SURGERIES SHORTER INPATIENT STAYS MORE HOPE FEWER SURGERIES SHORTER INPATIENT STAYS MORE HOPE